randomization – Page 30 – Communicable Diseases Research

Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

A short, animated video to improve good COVID-19 hygiene practices: a structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 age Algorithm anonymously APC Arm avoidance Behavioral intent behavioural blinded changes in clinical component control arm control group country COVID-19 COVID-19 outbreak Developed dissemination Effect Effectiveness Effects element eligible English Entertainment-education excluded expected experiment Face masks female FIVE France French Germany Gorilla highest Host hygiene IMPROVE include Interaction Intervention intervention arm investigator investigators item knowledge List experiment male media Medicine Novel coronavirus number objective outcome outcome measure parallel group participant Participants physical contact Placebo platform Prevalence Prevent Primary outcome Prolific Academic protocol question questionnaire randomised controlled trial randomization randomize Randomized Randomized controlled trial Randomly RCT reached receive recruit recruited reduce Registered secondary outcome sequence Sex social distancing Spain Spanish Spread spread of COVID-19 Stanford Study protocol submitted The United States total sample size Treatment treatment group Trial United Kingdom was collected washing hand washing hands website
[DOI] 10.1186/s13063-020-04449-1 PMC 바로가기 [Article Type] Letter

Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hour acute respiratory distress syndrome addition Administered Anakinra anti-IL-1 anti-IL-6 anti-IL-6 receptor antibody Bacterial Belgium binding blinded blockade Blood characterized chest X-ray chimeric clinical Clinical improvement Combination composed Coronavirus infection COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 patient CT scan death defined discharge dissemination dose drug Effectiveness element EudraCT excluded experimental arm factorial design Fungal infection hospital hospital discharge Hospitalized hospitals hypoxia hypoxic respiratory failure ICU IL-1 IL-6 IL-6 blockade IL-6 receptor interleukin 1 blockade interleukin 6 blockade Intravenous injection Invasive mechanical ventilation LDH lymphopenia mechanical ventilation non-invasive ventilation number objective on mechanical ventilation open label Open-label outcome oxygen Oxygenation paO2/fiO2 participant Participants Patient patients with COVID-19 Phase 3 primary end point protocol randomisation randomised randomised controlled trial randomization Randomized receive receptor recruited recruitment Registered response Sample size Serum ferritin siltuximab standard care Standard of care status Study protocol subcutaneous injection supplemental oxygen syndrome System systemic cytokine systemic cytokine release syndrome Tocilizumab treated Trial usual care was selected Web website
[DOI] 10.1186/s13063-020-04453-5 PMC 바로가기 [Article Type] Letter

Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 access acute respiratory syndrome addition age anticipated assigned Asymptomatic Baltimore baseline blinded blocked Bone marrow Boston Care Chloroquine clinically suspected close contact Complete Compound Concomitant concomitant use conducted Contact coronavirus coronavirus disease cough COVID-19 criteria current Date defined determine Diagnosis disorder dissemination Efficacy element eligible eligible participant etiology excluded first dose HCQ Health care worker healthcare worker history Hospitalized household household contact Hydroxychloroquine hypersensitivity incidence index case Infection Intervention leukocyte Los Angele medication moderate multisite neutropenia New Orlean New York City number objective outcome participant PCR-confirmed Pharmacist polymerase chain polymorphonuclear Post-exposure prophylaxis Prevent Primary outcome prolonged exposure Prophylaxis protocol psoriasis randomised randomised controlled trial randomization Randomized receive receiving Registered registry renal impairment responders resulting Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR test Seattle Secondary objective Seven severe liver disease Shortness of breath statistical statistician stratified study drug study period Study protocol subjective fever syndrome Tamoxifen telehealth therapy Tolerability Treatment Trial Vaccine virus website women
[DOI] 10.1186/s13063-020-04446-4 PMC 바로가기 [Article Type] Letter

Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 95% CI absence addition administration of hydroxychloroquine Admission aerosol-generating procedures allergy analyzed Anesthesia antibody approved ARMS assigned balanced randomization blind Cancer Cantabria carried CDC Cell Chemoprophylaxis clinical Clinical data clinically coated Committee comparator Comparator group computer-generated control group Controlled Controlled clinical trial Controlled trial coronavirus COVID COVID-19 criteria CURB current detect Determination disease dissemination double blind double-blind dropout rate Efficacy Efficacy and safety element ELISA kit Emergency Endocrine estimate Ethics Euroimmun Evidence evidence of Germany GRADE greater group Health Health authority health-care healthcare personnel Healthcare professional healthcare professionals heart heart failure help hematological high risk hospital Hydroxychloroquine hydroxychloroquine sulfate hygiene Hypothesis ICU IDT IgA IgG IgM and IgG immune immunodeficiency in vitro incidence include Infection inhibit intensive care unit Intervention investigator kidney lactation liver measure Measures Medicine Negative PCR neurological New York number observation period outcome participant PCR performed Personal protective equipment Placebo positive positive SARS-CoV-2 PCR positive serology Pregnancy presenting Prevalence Primary outcome probes product professional Prophylaxis Prospective PROTECT Protective protocol Psychiatric randomised randomised controlled trial randomization Randomized randomized trial RCT receive recruitment reduce reported responsible risk RT-PCR Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR sequence Seroconversion serological serology severity Significant single center single-center study social distancing Spain Spanish Standard Statistical power status Study protocol subject Support Symptom symptomatic and asymptomatic Tablet Takara Taking Tamoxifen Transmission Treatment two-tailed university Vaccine virus website while
[DOI] 10.1186/s13063-020-04400-4 PMC 바로가기 [Article Type] Letter

A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 age analogue anticipated assigned Asymptomatic blinded bpm Characteristics clinical trial comparator components Contact Controlled trial coronavirus disease COVID-19 COVID-19 symptom COVID19 Date deficiency develop Diabetes Mellitus Diagnosis disease dissemination dose double-blind drug Efficacy Efficiency eight element enrolled enrolment EU Clinical Trial evaluate evaluate the effect exclusion criteria experimental arm female participant Final Glucose haloperidol healthcare healthcare worker Healthcare workers hematological Hemodialysis hepatitis B Hereditary high risk history HIV HIV infection hospital hypersensitivity IgM/IgG immune immunosuppressive incidence Inclusion Infection Inflammatory cytokine Intervention less lymphopenia male melatonin men and women multicenter myasthenia gravis number objective outcome participant Patient PCR Placebo polymerase chain post-symptom onset Premenopausal Prevent prophylactic treatment Prophylaxis protocol Ramón randomisation randomised randomised controlled trial randomization Randomized Rapid test receiving recruited renal failure Research Retinitis rheumatoid arthritis risk RT-PCR Sample size SARS-CoV 2 SARS-CoV-2 SARS-COV-2 infection SAS version 9.4 secondary sequence Seroconversion severe COVID-19 severity of COVID-19 Sex Spain Spanish statistical status stratified study drug Study protocol symptomatic infection symptomatic SARS-CoV-2 infection Treatment Trial two-arm parallel ulcerative colitis understanding urinary pregnancy test Vasculitis website weight women
[DOI] 10.1186/s13063-020-04436-6 PMC 바로가기 [Article Type] Letter

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial

중증 COVID-19 성인 환자에 대한 정맥 주사 렘데시비르의 효능 및 안전성 평가: 무작위 배정, 이중 맹검, 위약 대조, 다기관 임상 3상 연구 프로토콜

Study Protocol

Published on 2020-05-242022-09-10
Journal: Trials [Category] MERS, SARS, 비임상,

[키워드] Administered Administrative information Adult patients Antiviral assigned asymptomatic infection breath category caused China Clinical efficacy Clinical improvement clinical manifestation clinical manifestations clinical status clinical trial concern conducted coronavirus disease Coronavirus disease 2019 Coronavirus infections Coronaviruses COVID-19 COVID-19 virus death defined discharge double-blind Efficacy Efficacy and safety Emergency enrolment event futility GS-5734 Health Organization highly pathogenic hospital in vitro in vivo experiments include Infection inhibitory inhibitory effect Inhibitory effects interim analysis Intravenous remdesivir intravenously laboratory-confirmed MERS-CoV Mild multicentre nucleoside Ordinal Scale Patient Phase 3 Placebo placebo-controlled placebo-controlled trial Pneumonia primary endpoint protocol Public public health emergency randomization Randomized Randomly Remdesivir reported required Respiratory failure SARS-CoV SARS-CoV-2 virus severe COVID-19 severe pneumonia severe viral pneumonia Spread Standard Study protocol Symptoms Treatment Trial Trial registration upper respiratory symptoms Viral Viral pneumonia virus infection World Health Organization Wuhan
[DOI] 10.1186/s13063-020-04352-9 PMC 바로가기 [Article Type] Study Protocol

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Original Article

Published on 2020-03-182022-11-01
Journal: The New England Journal of Medicine [Category] COVID-19, MERS, SARS,

[키워드] 1:1 95% CI 95% confidence interval addition adverse event adverse events Analysis assigned benefit breathing ambient air cause caused Chinese clinical Clinical improvement conducted creation defined detectable development discharge drug effective fraction Future Gastrointestinal hazard ratio help hospital Hospitalized laboratory-confirmed SARS-CoV-2 infection less Lopinavir–ritonavir Major median time modified intention-to-treat New Open-label oxygen oxygen saturation Patient percentage primary end point randomization Randomized Randomly receive Respiratory illness Result SARS-CoV-2 SARS-COV-2 infection Science Serious Adverse Event seven-category ordinal scale standard care technology Treatment Trial Viral RNA
[DOI] 10.1056/NEJMoa2001282 PMC 바로가기 [Article Type] Original Article

COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trial

DEXamethasone(CoDEX)으로 치료된 COVID-19 관련 ARDS: 무작위 시험에 대한 연구 설계 및 근거

Original Article

Published on 2020-01-012022-08-13
Journal: Revista Brasileira de Terapia Intensiva [Category] 임상,

[키워드] 350 patient 350 patients 48 hour 48 hours 6-level ordinal scale acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Adrenal cortex hormones Adult patients all-cause mortality rate all-cause mortality rates assessment Berlin criteria caused clinical status clinical trial Control control group Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 coronavirus disease 2019 - COVID-19 Corticosteroid Corticosteroides Corticosteroids COVID-19 COVID-19-associated ARDS Cuidados críticos days alive defined develop Dexametasona Dexamethasone dexamethasone 10mg IV dexamethasone 20mg intravenous early-onset Effectiveness Eligible patients evaluate evaluated failure followed by group hospitalized patient hospitalized patients Infection intensive care intervention group intravenous Invasive mechanical ventilation less mechanical ventilation mechanical ventilation duration moderate mortality rates multicenter Non-COVID-19 non-COVID-19 acute respiratory distress syndrome objective occur once daily Open-label Ordinal Scale outcome pandemic Patient patients with moderate Pneumonia Pragmatic Primary outcome randomization Randomized randomized trial Randomly receive respiratory respiratory compromise respiratory distress Respiratory distress syndrome Respiratory distress syndrome, adult Síndrome do desconforto respiratório do adulto SARS-CoV-2 SARS-COV-2 infection score secondary Secondary outcomes severe acute respiratory syndrome Coronavirus Spread standard treatment stratified Study design syndrome treated Trial unit discharge ventilator-free day Ventilator-free days Viral Viral pneumonia
[DOI] 10.5935/0103-507X.20200063 PMC 바로가기 [Article Type] Original Article

The Efficacy and Safety of a Fixed Combination of Chinese Herbal Medicine in Chronic Urticaria: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Original Research

Published on 2018-12-182024-09-02
Journal: Frontiers in Pharmacology [Category] 대상포진,

[키워드] Chinese herbal medicine chronic urticaria clinical trial double-blind placebo-control randomization
[DOI] 10.3389/fphar.2018.01474 PMC 바로가기 [Article Type] Original Research